Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Phase 1
21(91.3%)
N/A
1(4.3%)
Phase 2
1(4.3%)
23Total
Phase 1(21)
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07523100Phase 1Not Yet Recruiting

A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.

Role: collaborator

NCT07453836Phase 1Not Yet Recruiting

Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia

Role: lead

NCT07236762Phase 1Recruiting

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Role: lead

NCT07075484Phase 1Completed

A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Role: lead

NCT07123519Phase 1Recruiting

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Role: lead

NCT07236801Phase 1Recruiting

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Role: lead

NCT07104721Phase 1Recruiting

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Role: lead

NCT07439029Phase 1Not Yet Recruiting

YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases

Role: collaborator

NCT07287930Phase 1Not Yet Recruiting

A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Role: collaborator

NCT05913804Phase 1Recruiting

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT06978647Phase 1Recruiting

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Role: lead

NCT06943937Phase 1Recruiting

A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

Role: lead

NCT06770504Phase 1Not Yet Recruiting

A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

Role: collaborator

NCT06379646Not ApplicableRecruiting

An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease

Role: lead

NCT04153279Phase 1Completed

CMV-TCR-T Cells for CM Virus Infection After HSCT

Role: collaborator

NCT04508842Phase 1Terminated

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

Role: collaborator

NCT04260945Phase 1Completed

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

Role: collaborator

NCT04156217Phase 1Completed

EBV-TCR-T Cells for EB Virus Infection After HSCT

Role: collaborator

NCT04260932Phase 1Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

Role: collaborator

NCT04506983Phase 1Suspended

GPC3-CAR-T Cells for the Hepatocellular Carcinoma

Role: collaborator